Roth Capital assumed coverage on shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in a research report sent to investors on Wednesday morning, MarketBeat reports. The firm issued a buy rating and a $32.00 price objective on the biopharmaceutical company’s stock.
GLMD has been the topic of a number of other reports. HC Wainwright restated a buy rating and issued a $18.00 target price on shares of Galmed Pharmaceuticals in a report on Friday, October 27th. Seaport Global Securities restated a buy rating and issued a $19.00 target price on shares of Galmed Pharmaceuticals in a report on Friday, October 6th. Maxim Group set a $14.00 target price on Galmed Pharmaceuticals and gave the stock a buy rating in a report on Thursday, October 5th. Finally, Zacks Investment Research upgraded Galmed Pharmaceuticals from a hold rating to a buy rating and set a $8.00 target price on the stock in a report on Wednesday, August 2nd. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $18.30.
Galmed Pharmaceuticals (NASDAQ GLMD) opened at $7.81 on Wednesday. Galmed Pharmaceuticals has a 1-year low of $3.04 and a 1-year high of $9.59.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
What are top analysts saying about Galmed Pharmaceuticals Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Galmed Pharmaceuticals Ltd. and related companies.